AM1476
Systemic Sclerosis (skin and lung fibrosis)
Phase 2Active
Key Facts
About AnaMar Medical
AnaMar Medical is a privately held, clinical-stage biotech company pioneering a novel anti-fibrotic therapy. Its lead asset, AM1476, is a highly selective 5-HT2B receptor antagonist that is Phase II-ready, supported by positive Phase I safety data and preclinical proof-of-concept. The company is seeking partnerships to advance its program in systemic sclerosis and leverage its platform in broader fibrotic disorders, combining therapeutic development with biomarker and genetic analysis for targeted treatment.
View full company profile